STUDresearch · Peptide
Afamelanotide (community / implant access discussions)
Also known as
Scenesse community talk · Afamelanotide implant · Scenesse · SCENESSE · MT-1 implant discussion · CUV1647 · NDP-MSH (implant context) · Melanotan I (clinical form) · afamelanotide 16 mg implant · [Nle4,D-Phe7]-α-MSH implant
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
SubQ implant
Tanning & melanocortin
Systemic pigmentation signal; licensed Scenesse is a clinician-inserted 16 mg SubQ implant, not a daily self-injected vial or nasal spray.
What people say
Afamelanotide/Scenesse discussion centers on EPP light tolerance, implant access and pigmentation. The licensed 16 mg implant is not an interchangeable version of a gray-market Melanotan I vial.
Doses people talk about
This is clinic-treated EPP, not a cosmetic self-titration chart. Historical vial amounts below are not implant-equivalent.
How it may feel
Patients describe greater freedom outdoors, but reactions can still occur. One first-implant account reports a mixed day-9 hike; early nausea, fatigue or dizziness and later skin/freckle darkening are separate parts of the experience.
Licensed EPP implant16 mg SubQ every 2 months
One clinician-inserted implant. The pivotal US pattern was 3 implants over ~6 months; annual use follows specialist and access context, not a fixed universal ceiling.
Vitiligo research, not EPP label16 mg monthly × 4
Published investigational implant-plus-NB-UVB work; separate from the EPP interval. Denser ~3-week trial schedules remain below as research context.
Historical solution research~0.08–0.21 mg/kg SC
The checked study describes 10 dosing occasions over 2 weeks, not 10 per day. Different formulation and research context; not a consumer schedule.
Half-life & effect duration
- Half-life in the body
- Controlled-release implantAbout 15 hours
- Injected solutionAbout 0.8–1.7 hours
- EMA / older summariesAbout 30 minutes; a separate source estimate
- Felt duration people report
- Patient experiencesImproved outdoor freedom; one describes a meaningful but imperfect outing on day 9
- Early implant symptomsTiredness, headache, dizziness or nausea during the first 1–3 days
Cycles people discuss
EPP schedules center on one implant every 2 months through higher-light periods, often ~3 in a seasonal account. Annual counts and off-season pauses depend on specialist care and access—not a bodybuilding PCT cycle.
Timing
Seasonal light exposure and clinic availability drive timing. The apparent implant half-life is ~15 hours; early symptoms, week-scale pigmentation and the ~60-day care interval are different clocks.
Stacks
Light-protection habits and twice-yearly skin examinations remain central. NB-UVB pairing belongs to investigational vitiligo care; MT-I vials, MT-II and PT-141 are comparisons, not routine implant companions.
Watch for
Hypersensitivity / anaphylaxis: Serious allergic reactions including anaphylaxis reported postmarketing — implants are placed in clinic settings with observation for a reason.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
~15 hours apparent half-life for the implant—not a free-vial or two-month clock.
The US label reports median Tmax 36 hours and last quantifiable concentration at 96 hours in 9/12 subjects. The EMA ~30-minute statement and historical SC solution beta-phase result (~0.8–1.7 hours in three men) are distinct contexts.
Apparent controlled-release PK cannot be transferred to a bolus vial, nasal product or a felt/tanning duration. Below quantification is not proof of zero drug.
- SCENESSE US prescribing information, revised August 2024 (opens in a new tab)Nine-page prescribing information, Reference ID 5427935: PDF page 2 §2.1; page 7 §12.3 (12-person PK study); page 8 §16 (2–8°C storage). Hypersensitivity and skin monitoring in §5.Manufacturer-hosted FDA prescribing-information PDF was read directly. The ~15-hour figure is apparent implant PK, not a free-SC solution half-life. Its clinical-trial analysis is not used to overwrite the legacy published-trial sunlight totals.
- SCENESSE EU product information (opens in a new tab)Current 26-page product-information PDF: printed page 2 §4.2, page 5 §4.7, page 9 §§5.1–5.2. Duration at specialist discretion, limited 4–6-implant/year data, ~30-minute statement, and release/quantification context.Full relevant label sections read. The ~30-minute text does not clearly identify a free-bolus human study and is not merged with the US implant estimate. Annual exposure experience is not a universal maximum.
- Skin pigmentation and pharmacokinetics of melanotan-I in humans (opens in a new tab)Ugwu et al., Biopharm Drug Dispos 1997;18:259–269. Complete abstract read through Europe PMC Core API for PMID 9113347: three male volunteers, SC dose range, ten doses over two weeks, beta-phase half-life 0.8–1.7 h and follow-up pigmentation.Complete abstract inspected, not full article. Historical solution study, n=3; IV and oral crossover details are distinct from the SC findings. Ten doses in two weeks does not support ten injections per day.
Felt duration people report
No dependable single-implant felt-duration window in the checked patient accounts.
One patient describes a meaningful but imperfect day-9 outing; another describes greater outdoor freedom during a trial and subsequent repeated care. Neither establishes a timed onset-to-offset window. Early 1–3-day symptoms and the ~60-day care interval are not benefit duration.
Selected, uncontrolled patient-association stories with ongoing treatment and changing light exposure. These do not quantify a typical offset or support cosmetic or gray-market-product equivalence.
- Margie Rose — first-implant EPP patient account (opens in a new tab)American Porphyria Foundation public member story, final first-implant paragraphs (rendered lines 85–88): written 15 days after insertion, describes a ~2-hour hike on day 9 and later minor hand/finger symptoms.Actual full patient story read; undated selected advocacy account, not a trial or cosmetic-user report. Light exposure and protection vary; it does not establish duration or guarantee complete protection.
- George Hodder — EPP trial and repeated-treatment experience (opens in a new tab)American Porphyria Foundation public member story, treatment/trial and outdoor-activity paragraphs (rendered lines 31–47); discusses a six-month trial, delayed willingness to test sunlight and treatment entering 2023.Actual full public story read. Repeated treatment, fear-driven behavior and access logistics confound onset and duration. No private patient groups or unlicensed-vial experiences are represented by this source.
- SCENESSE EU product information (opens in a new tab)Current 26-page product-information PDF: printed page 2 §4.2, page 5 §4.7, page 9 §§5.1–5.2. Duration at specialist discretion, limited 4–6-implant/year data, ~30-minute statement, and release/quantification context.Full relevant label sections read. The ~30-minute text does not clearly identify a free-bolus human study and is not merged with the US implant estimate. Annual exposure experience is not a universal maximum.
What people say
- QoL / outdoor function (EPP patients): Community and observational reports emphasize more outdoor work, travel, and social flexibility when implants are timed to spring–summer light. forum
- Aesthetic spillover interest: Non-EPP forums sometimes call Scenesse a “cleaner” clinical tan path than MT-II (more MC1R-selective lore, less libido/appetite drama) — but real access is disease/clinic-restricted and cost-gated. forum
- EPP pain-free light (primary Phase 3 signal): US CUV039-class summary — median ~69.4 hours pain-free direct sun (10:00–18:00) over ~6 months on Scenesse vs ~40.8–41 hours on vehicle (~70% more pain-free time in one common retelling). trial
- EPP EU trial signal (CUV029-class): Longer median pain-free time and fewer phototoxic reactions vs placebo over ~9 months with more frequent seasonal implant counts in supportive work. trial
- Fewer phototoxic flares: Reduced phototoxicity burden during treated high-sun seasons in EPP cohorts. trial
- Long-term EPP registries: Multi-year observational cohorts (e.g. Biolcati-class, n≈115 over years) report sustained clinical benefit and generally good tolerability under repeated implants — disease-use dataset, not cosmetic tanning. trial
- Moles/freckles darken: Pre-existing nevi and freckles commonly darken as pigment rises; drives the twice-yearly full-body skin-exam recommendation. trial
- Vitiligo adjunct (investigational, not EPP label): Multicenter work: afamelanotide implant + NB-UVB faster/superior repigmentation vs NB-UVB alone in generalized/nonsegmental vitiligo (monthly implant class in published work; denser schedules in later trials). trial
- PMLE pilot signal: Older pilot used a 20 mg slow-release implant class in polymorphic light eruption with reduced dermal symptoms vs control in small work — not approved EPP dosing and not a consumer protocol. trial
- Solar urticaria / other photodermatoses: Small implant cohorts and exploratory write-ups exist; not approved indications. trial
- Hailey-Hailey / acne exploratory notes: Sparse open-label implant signals appear in derm reviews — not community dose drivers. trial
- Still not UV-proof: Label and patient materials keep sun-protection measures during EPP treatment; pigment does not erase phototoxicity risk. trial
- Diffuse skin darkening: Progressive eumelanin-type tan is nearly universal after implant — expected pharmacology, not a “side” in the EPP label framing. trial
Doses people talk about
- Not vial-equivalent math: Community “0.25–0.5 mg/day MT-I load” or “1 mg × 10 days” charts do not equal controlled-release 16 mg implant exposure, Cmax, or release curve. forum
- Research-chem contrast (identity, not equivalence): Gray-market lyophilized “Melanotan I / afamelanotide” vials are discussed at mcg–mg daily SC bands elsewhere; they are not licensed Scenesse and may be mislabeled. forum
- Cost/access as de-facto “dose limiter”: Specialty-drug pricing and prior auth dominate real-world implant frequency more than patient self-titration — secondary write-ups sometimes quote tens-of-thousands-USD per implant class figures before insurance. forum
- Access > titration: For this product, “dosing talk” in patient groups is mostly insurance approval, trained clinic location, and seasonal scheduling — not syringe-unit debates. forum
- Framing: This card prioritizes licensed implant parameters and access discussion — not cosmetic advice and not gray-market vial mcg protocols (see Melanotan I profile for research-vial chart culture). forum
- Licensed strength: One Scenesse implant = 16 mg afamelanotide in a solid white/off-white rod ~1.7 cm long × ~1.5 mm diameter, PLGA / poly(DL-lactide-co-glycolide) matrix. trial
- Site / technique: Inserted above the anterior supra-iliac crest (hip) with a dedicated implantation cannula (SFM-class tooling in US materials) by a healthcare professional trained on the procedure. trial
- Who inserts: Not home DIY; proficiency + manufacturer training is an explicit administration requirement. trial
- Per high-sun season: Common EPP practice talk ~3 implants spanning expected increased sunlight (spring into early autumn class). trial
- Annual implant-count discussion: Older patient/derm summaries describe ~3–4 implants/year, not a universal current ceiling. The current EU SmPC leaves duration to specialist discretion; supportive CUV029/PASS contexts have described five or up to six implants/year at two-month spacing, and the SmPC notes limited data for 4–6 implants/year. trial
- Interval (label): Single implant subcutaneously about every 2 months (~60 days); higher dose or more frequent administration is generally treated as experimental by payers. trial
- Pivotal US trial pattern (CUV039): Three 16 mg implants at two-month intervals over ~6 months vs vehicle. trial
- Pivotal EU trial pattern (CUV029-class): More implants across a longer high-sun window (supportive nine-month designs with ~five-dose class exposure). trial
- Vitiligo trial schedules (investigational, denser than EPP label): Published multicenter work used 16 mg monthly × 4 after a month of NB-UVB priming; ongoing Phase 3-class designs discuss 16 mg every ~3 weeks for months (multi-implant courses) + NB-UVB — not EPP standard of care. trial
- Historical free-peptide SC (separate from implants): Older retellings claim multi-daily injections, including “about ten times/day” lore. The checked 1997 study instead describes ~0.08–0.21 mg/kg SC on ten dosing occasions over two weeks, not ten per day. These weight-based multi-day research courses are not Scenesse or a consumer schedule. trial
How it may feel
- Weeks 1–3: Base tan and freckle darkening become more obvious while EPP light-protection habits continue. In one public first-implant account, a ~2-hour hike on day 9 felt transformative but still caused minor finger/hand symptoms later; this is a personal light-tolerance report, not a promise of being UV-proof. forum
- Weeks 4–8: Color and practical outdoor tolerance often described as plateaued until the next ~60-day implant. forum
- Clinic day 0: Local anesthetic / cannula insertion above hip (anterior supra-iliac crest class); short post-insert observation commonly discussed for hypersensitivity. trial
- Hours 0–72: Early tiredness, headache, dizziness, nausea or somnolence are discussed after insertion; the EU label highlights potential driving impairment especially within 72 hours. Older EPP patient accounts describe the first 1–3 days as a “systemic feel” window, not a measured drug-clearance or benefit-duration endpoint. trial
- Days 1–7 implant site: Bruising, tenderness, redness, local darkening, irritation, or a palpable nodule can appear; implant-site reaction was the top AE in pooled Scenesse vs vehicle data (~21% vs ~10%). trial
- ~Day 7 pigment biology: Melanin-density measures in implant photodermatosis cohorts rise early; visible tan may still lag without ambient light. trial
- Days ~7–15 peak pigment window (research cohorts): Solar-urticaria implant work described mean melanin density peaking around day 15 and remaining elevated at day 60 after a single 16 mg implant. trial
- ~Day 60 re-implant cadence: Licensed schedule is one implant about every 2 months in high-light seasons — not daily blood-level chasing. trial
Cycles people discuss
- Off-season pause: Fewer or no implants in low-light months is common in EPP practice talk when light burden drops. forum
- Annual re-starts: Many EPP patients re-engage each high-sun season if coverage and clinic access continue. forum
- No bodybuilding PCT model: Discourse is disease-season and dermatology monitoring, not HPTA “post-cycle therapy.” forum
- Do not stack implant + DIY MT-I vials: Community serious guides treat concurrent gray-market melanotan with Scenesse as identity/safety confusion, not a smart load. forum
- Seasonal blocks (label spirit): One implant every 2 months prior to expected and during increased sunlight exposure; overall duration at specialist discretion. trial
- ≥60-day spacing: At least about two months between insertions is the standard re-dose fence. trial
- High-sun course: Often start before peak UV season and continue through it (~3 implants common narrative). trial
- Vitiligo research “courses”: Fixed multi-month implant series tied to phototherapy calendars — investigational, denser than EPP label, clinic-only. trial
- Long multi-year EPP use: Registries support repeated seasonal implants under care without a mandatory multi-month receptor “reset” off-cycle. trial
Timing
- vs research MT-I vials: Daily/near-daily vial use appears in community discussion. Short free-peptide residence after bolus SC is the forum rationale, not proof of a validated regimen derived from solution PK; the implant is not “split into daily 16 mg/60.” forum
- Different formulation clocks: Older free-peptide retellings quote ~30 minutes and very frequent SC dosing. The EMA SmPC also states ~30 minutes without specifying a free-bolus study context; the checked 1997 SC solution study reports a beta-phase half-life of ~0.8–1.7 hours in three male volunteers. US controlled-release implant PK instead reports an apparent ~15 hours. None establishes a ten-injections-per-day requirement. trial
- Implant absorption (label PK): Median Tmax ~36 hours after single SC implant. trial
- Implant exposure numbers (label-class healthy adults): Mean Cmax ~3.7 ± 1.3 ng/mL; mean AUC0-inf ~138.9 ± 42.6 h·ng/mL; high inter-subject variability. trial
- Apparent half-life under implant conditions: ~15 hours when administered as the controlled-release implant (not the free-bolus number). trial
- Last quantifiable plasma (implant study): In 9 of 12 healthy adults, the last quantifiable concentration was at ~96 hours after a single implant. That is an assay/sampling observation, not proof that all drug is gone; it is separate from the next ~60-day implant and the longer-lasting pigment response. trial
- Release curve (SmPC-class): Most active substance released within the first ~48 hours; >90% released by day 5 — matrix/biology then carry pigment effects, not steady plasma drug for two months. trial
- Pigment lag / hold: Visible tan and photoprotection outlast plasma because melanogenesis and epidermal pigment are tissue processes over weeks. trial
- Re-dose logic: Biodegradable PLGA-class implant + clinical ~60-day interval is a schedule of care, not daily trough chasing. trial
- Oral: Free peptide is not a practical oral drug in early PK (no meaningful oral delivery narrative for this molecule). trial
- Renal/hepatic impairment: Effect on afamelanotide PK not characterized on label — specialist caution territory. trial
- Still protect from light: Keep EPP light-protection measures during treatment; implant is not a force-field. trial
More on what it is
- Why this card exists: Community talk about Scenesse access, implant schedules, cost/insurance, and “is this the same as Melanotan I vials?” clusters separately from pure gray-market MT-I dose charts. forum
- Not the same as: Melanotan II (“Barbie drug” / nasal tanning sprays), PT-141/bremelanotide, sunscreen, DHA spray tan, or unlicensed online “MT-1 implant / fake Scenesse” products. forum
- Research lens: Keep EPP Phase 3 implant data, investigational vitiligo/PMLE implant schedules, EPP patient access stories, and gray-market vial talk as separate streams — do not treat them as interchangeable dosing. forum
- Evidence honesty: High-quality RCTs exist for EPP implants; cosmetic/access-spillover forums are thinner and often confuse implant PK with research-chem vial protocols. forum
- What it is: Synthetic linear 13-amino-acid α-MSH analog ([Nle4,D-Phe7]-α-MSH / NDP-MSH), known as afamelanotide; Scenesse is the licensed 16 mg controlled-release implant form. trial
- Approved use (only label indication): Adult erythropoietic protoporphyria (EPP) — increase pain-free light exposure under specialist care (FDA 2019; EMA earlier EU authorization for EPP phototoxicity prevention). trial
- Molecule vs product: The active peptide is the same chemical lineage as research “Melanotan I,” but licensed exposure is a single preformed PLGA-class rod inserted by a trained clinician — not DIY mcg math. trial
- Why implants exist: Scenesse supplies controlled-release exposure rather than a daily self-injected vial. Older free-peptide summaries repeat a ~30-minute half-life and very-frequent-injection narrative; the EMA SmPC quotes ~30 minutes without a clear free-bolus study context, whereas US implant PK gives an apparent ~15 hours. These are not interchangeable clocks. trial
Stacks
- vs Melanotan II (compare, do not co-use casually): Forums contrast MC1R-selective implant/MT-I path vs multi-receptor MT-II (tan + libido + appetite + stronger nausea); stacking both is generally discouraged as redundant pigment drive plus more sides. forum
- vs research MT-I vials: Comparison is about access/cost/legality and PK form — not a recommended dual exposure. forum
- vs PT-141 / bremelanotide: Separate melanocortin lane (sexual desire); not a standard Scenesse companion. forum
- Access logistics stack: Specialty pharmacy, trained inserter clinic, insurer prior authorization, and sometimes manufacturer patient-assistance programs. forum
- Not Wolverine / GLOW / KLOW: Stays in melanocortin–photoprotection lane; not BPC-157/TB-500/GHK-Cu injury aesthetics. forum
- Nausea management (non-peptide): Hydration, light meals, rest during first 72 hours — less anti-emetic-stack culture than MT-II load threads. forum
- Antioxidant blog add-ons: Occasional lifestyle mentions (e.g. general skin antioxidants) are confounded and not validated implant potentiators. forum
- Sun-behavior co-protocol (label-aligned): Implant + clothing, shade, and sunscreen/light-protection habits — not a solo UV shield. trial
- Dermatology monitoring stack: Full-body skin examination about twice yearly while moles/freckles darken. trial
- Vitiligo research pairing: Implant + narrowband UVB phototherapy in investigational protocols — clinic phototherapy calendar, not home “stack.” trial
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage depends on product: Licensed Scenesse is refrigerated at 2–8°C and protected from light in the clinic supply chain. Older generic research-product talk says cool, dry and away from light per the seller label; that is not the licensed implant's storage specification. Anything after first use remains product-specific, not a universal forum SOP. trial
Watch for
- Product identity risk: Unregulated products marketed as “Scenesse,” “afamelanotide implant,” or “MT-1 implant” online may be mislabeled, underdosed, contaminated, or actually Melanotan II; Clinuvel and regulators have warned about counterfeit melanotan branding. forum
- Cost / access distress: Community EPP threads frequently cite denials, prior-auth delays, and high list prices as practical harms even when the drug is clinically indicated. forum
- Implant site reactions (most common): Bruising, pain, redness/erythema, irritation, pruritus, swelling, discoloration, hemorrhage, hypertrophy, nodule; injection-site AE language and expelled implant appear in pooled tables (~21% Scenesse vs ~10% vehicle). trial
- Nausea: ~19% class incidence in pooled Scenesse AE tables — usually early after insertion. trial
- Other common systemic AEs (>2% class): Oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevus notation, respiratory tract infection, non-acute porphyria coding, skin irritation. trial
- Hyperpigmentation: Diffuse tan + local darkening at site — expected pharmacology for almost all treated patients. trial
- Mole / freckle darkening: Nevi and freckles may darken or become more noticeable; full-body exams ~twice yearly are recommended on label materials. trial
- Hypersensitivity / anaphylaxis: Serious allergic reactions including anaphylaxis reported postmarketing — implants are placed in clinic settings with observation for a reason. trial
- Not UV-proof / not a burn cure: Pigment does not eliminate EPP phototoxicity; maintain light-protection measures. trial
- Partial unblinding in trials: Skin darkening can unblind patients and investigators — a known limitation when interpreting subjective pain-free-time endpoints. trial
- Pregnancy / lactation: Limited human data; not a studied cosmetic pathway; off-label aesthetic use lacks long-term safety databases. trial
- Pediatric use: Not established as standard EPP pediatric dosing in the adult-label paradigm; specialist territory only. trial
- Investigational denser schedules: Monthly or every-3-week vitiligo-trial implant courses change cumulative exposure vs EPP every-2-months label — not DIY transferable. trial
- Skin-cancer vigilance (class concern): Darkening of nevi can obscure or mimic change; agencies and derms urge monitoring with any melanocortin tanning exposure, licensed or not. trial
- Renal/hepatic unknowns: PK in impairment not characterized — caution for comorbid patients under specialist care. trial
- Research-only / not consumption framing: Gray-market discussion of vials or fake implants is research-identity talk, not a use recommendation. forum
Evidence mix
More trial/lab tags than forum tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.